NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

7248.50 -56.50 (-0.77%)

New 52W High in past week

336.4K NSE+BSE Volume

NSE 24 Jul, 2026 3:31 PM (IST)

192,424.9

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Divi's Laboratories is on 01 Aug 2026 for the purpose of Quarterly Results See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

08 Jul 2026

7248.50

-0.77%

Divis Laboratories Ltd – Q1FY27 Preview:

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 15.3% / 20% / 18.2% for the period of FY26-FY28.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

28 May 2026

7248.50

-0.77%

Valuation

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 15.3% / 20% / 18.2% for the period of FY26-FY28.

Number of FII/FPI investors increased from 842 to 864 in Jun 2026 qtr.

Divi's Laboratories Ltd.

25 May 2026

7248.50

-0.77%

Divi's Laboratories (DIVI IN) Q4FY26 Result Update EBITDA miss; Peptide opportunities key for growth ACCUMULATE

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY26 EBITDA missed our estimates due to lower gross margin. Revenues were largely aided by CS segment and currency tailwind. Mgmt indicated inventory levels may increase further in Q1FY27E to ensure uninterrupted operations. We expect stable margins in FY27 and expect revenue to accelerate from FY28 as commencement of some CDMO and contrast media contracts along with peptide revenue scale up. Our FY27E/FY28E EPS estimates stand cut by 2-4%. We expect 19% EBITDA and PAT CAGR over FY26-28E. At CMP, stock is trading at 52x...

Divi's Laboratories has gained 20.58% in the last 6 Months

Divi's Laboratories Ltd.

24 May 2026, 12:00AM

7248.50

-0.77%

Divi's Labs (HOLD): Margin headwinds to persist in near term

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 3.4%/10%/1 below our estimates. EBITDA Margin was reported 235 bps below our estimates at 33%

Divi's Laboratories has gained 20.58% in the last 6 Months

Divi's Laboratories Ltd.

06 Apr 2026

7248.50

-0.77%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The outlook remains positive, supported by Divi's strong positioning in custom synthesis and a diversified pipeline, with management highlighting active engagement with global innovator customers and multiple projects progressing through development and validation. Ongoing capacity additions along with a focus on disciplined execution and supply reliability are expected to support future growth, while the nutraceuticals business continues to provide healthy momentum and diversification. The company has also completed construction of a dedicated peptide facility, strengthening its capabilities in this fast-evolving segment, and...

Deven Choksey increased Accumulate price target of Divi's Laboratories Ltd. to 7157.0 on 08 Jul, 2026.

Divi's Laboratories Ltd.

20 Nov 2025

7248.50

-0.77%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.

Deven Choksey increased Accumulate price target of Divi's Laboratories Ltd. to 7157.0 on 08 Jul, 2026.

Divi's Laboratories Ltd.

10 Nov 2025

7248.50

-0.77%

Divi's Labs (HOLD): Key molecule LOE to risk upside growth in Custom Synthesis

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 3%/9%/11% above estimates. EBITDA margin reported 170 bps above estimates.

Number of FII/FPI investors increased from 842 to 864 in Jun 2026 qtr.

Divi's Laboratories Ltd.

10 Nov 2025

7248.50

-0.77%

Divi's Laboratories (DIVI IN) Q2FY26 Result Update Peptides...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Deven Choksey increased Accumulate price target of Divi's Laboratories Ltd. to 7157.0 on 08 Jul, 2026.

Divi's Laboratories Ltd.

09 Nov 2025

7248.50

-0.77%

Generics continue to drag growth, CS outlook unchanged

Sell: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q2FY26 result was in line with our expectations on all fronts. Constant currency growth slowed down to ~10.8% vs. 15% QoQ and 18% in FY25.